retatrutide clinical trials obesity ⭐️topline results from TRIUMPH-1, a Phase 3 trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with or “overweight” Lilly's New Obesity Drug Retatrutide

These data come from Cosmos, a dataset created in collaboration with a community of Epic health systems representing more than 300 million patient records from 1,900 hospitals and more than 42,000 clinics from all 50 U.S

ATTENTION All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY

doi: 10.3892/ol.2017.7211 57 SherajIGurayNTBanerjeeS

This has a cyanide molecule attached to it so this has to be cleaved off and then the body adds a methyl or hydroxyl group to it

The NJEM study shows that 14% of patients using 1mg retatrutide experienced nausea, while 18-36% with 4mg, 17-60% with 8 mg, and 45% with 12 mg had nausea compared to 11% in the placebo group